Literature DB >> 7410539

Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology.

F Camanni, A R Genazzani, F Massara, V de Leo, G M Molinatti, E E Müller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7410539     DOI： 10.1210/jcem-51-3-650

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  6 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  Nomifensine in hyperprolactinemic states.

Authors:  E E Müller; F Camanni; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

3.  Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas.

Authors:  F Iannotta; P Fachinetti; A Fachinetti; G Pinotti; L Usellini
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

4.  Multicentric experience on the acute effect of nomifensine in hyperprolactinemic women.

Authors:  F Minuto; A Barbarino; G Baviera; G Mazzocchi; L De Marinis; R Leonardi; D Bernasconi; E Menini; G Maira; C Anile
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

Review 5.  Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.

Authors:  E E Müller; V Locatelli; S Cella; A Peñalva; A Novelli; D Cocchi
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

6.  Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia.

Authors:  E Ghigo; E Ciccarelli; A Novelli; M Massobrio; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.